Breast Cancer; Findings in breast cancer reported from University of Pennsylvania
2008 APR 17 - (NewsRx.com) -- According to recent research from the United States, "Parvin-beta is a focal adhesion protein downregullated in human breast cancer cells. Loss of Parvin-beta contributes to increased integrin-linked kinase activity, cell-matrix adhesion, and invasion through the extracellular matrix in vitro."
"The effect of ectopic Parvin-P expression on the transcriptional profile of MDA-MB-231 breast cancer cells, which normally do not express Parvin-beta, was evaluated. Particular emphasis was placed upon propagating MDA-MB-231 breast cancer cells in three-dimensional culture matrices. Interestingly, Parvin-beta reexpression in MDA-MB-231 cells increased the mRNA expression, serine 82 phosphorylation (mediated by CDK9), and activity of the nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPAR gamma), and there was a concomitant increase in lipogenic gene expression as a downstream effector of PPAR gamma. Importantly, Parvin-beta suppressed breast cancer growth in vivo, with associated decreased proliferation," wrote C.N. Johnstone and colleagues, University of Pennsylvania (see also Breast Cancer).
The researchers concluded: "These data suggest that Parvin-P might influence breast cancer progression."
Johnstone and colleagues published their study in Molecular and Cellular Biology (Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation. Molecular and Cellular Biology, 2008;28(2):687-704).
For additional information, contact A.K. Rustgi, University of Pennsylvania, Abramson Cancer Center, Dept. of Med & Genetics, 600 Clinic Research Bldg, 415 Curie Blvd., Philadelphia, PA 19104, USA.
Publisher contact information for the journal Molecular and Cellular Biology is: American Society Microbiology, 1752 N St. NW, Washington, DC 20036-2904, USA.
This article was prepared by Blood Weekly editors from staff and other reports. Copyright 2008, Blood Weekly via NewsRx.com.
Breast Cancer; Studies in the area of breast cancer reported from N.J. Robert and co-researchers
20 September2007
Blood Weekly
(c) Copyright 2007 Blood Weekly via NewsRx.com
2007 SEP 20 - ( NewsRx.com) -- According to a study from the United States, "It is important when treating a patient who has advanced breast cancer to establish the biologic characteristics of the tumor."
"In addition to knowing the hormone receptor status (estrogen and progesterone), human epidermal receptor 2 (HER2) should be evaluated. The measurement of this parameter is essential to optimizing the systemic management," wrote N.J. Robert and colleagues.
The researchers concluded: "This article reviews the biology of HER2, testing for HER2, clinical studies evaluating HER2-based therapies, side effects (specifically cardiotoxicity), and strategies for HER2-based therapies."
Robert and colleagues published the results of their research in Hematology - Oncology Clinics of North America (HER2-positive advanced breast cancer. Hematology - Oncology Clinics of North America, 2007;21(2):293+).
For additional information, contact N.J. Robert, US Oncology Research Network, Fairfax No Virginia Hematology Oncology, 8503 Arlington Blvd., 400, Fairfax, VA 22031, USA.
The publisher of the journal Hematology - Oncology Clinics of North America can be contacted at: W B Saunders Co-Elsevier Inc., 1600 John F Kennedy Boulevard, Ste. 1800, Philadelphia, PA 19103-2899, USA.
This article was prepared by Blood Weekly editors from staff and other reports. Copyright 2007, Blood Weekly via NewsRx.com.